| Autor: |
Stephenson, C M, Bigliani, V, Jones, H M, Mulligan, R S, Acton, P D, Visvikis, D, Ell, P J, Kerwin, R W, Pilowsky, L S |
| Zdroj: |
British Journal of Psychiatry; Nov2000, Vol. 177, p408-415, 8p |
| Abstrakt: |
Background: Selective action at limbic cortical dopamine D(2)-like receptors could mediate atypical antipsychotic efficacy with few extrapyramidal side-effects.Aims: To test the hypothesis that quetiapine has 'limbic selective' D(2)/D(3) receptor occupancy in vivo.Method: The high-affinity D(2)/D(3) ligand [(123)I]-epidepride and single photon emission tomography were used to estimate D(2)/D(3) specific binding and an index of relative percentage D(2)/D(3) occupancy in striatal and temporal cortical regions for quetiapine-treated patients (n=6). Quetiapine-, and previously studied typical-antipsychotic- and clozapine-treated patients were compared.Results: Mean (s.d.) relative percentage D(2)/D(3) receptor occupancy by quetiapine was 32.0% (14.6) in striatum and 60.1% (17.2) in temporal cortex (mean daily dose 450 mg: range 300-700 mg/day). Quetiapine treatment resulted in limbic selective D(2)/D(3) blockade similar to clozapine and significantly higher than typical antipsychotics.Conclusions: Preliminary data suggest that limbic selective D(2)/D(3) receptor blockade is important for atypical drug action. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
